Several studies have illustrated the interaction between adipokines (including adiponectin and resistin) and adenosine 5' monophosphate-activated protein kinase (AMPK), and highlighted AMPK as a potential target for the development of tissue-specific AMPK modulators in the treatment of T2DM and MS [50]. This evidence concerns the gene RETN and myeloid sarcoma.